Influence of Acute Myeloid Leukemia Progression on the Prognosis of 831 Patients with Myelodysplastic Syndromes from the Argentine Database

Conclusion The use of IPSS-R and WPSS systems simultaneously may help pointing out those patients that would require a more aggressive treatment; nevertheless, more efforts are need to improve identification of those lower risk patients whose survival is significantly reduced by AML progression. Teaser In our retrospective review of 831 patients, 158 progressed with a very poor outcome (median survival after evolution: 3.5 months). The survival of patients with adverse karyotypes or with higher IPSS-R or WPSS risk was not affected upon comparison of patients with or without evolution to AML. Our results may help individualizing those patients that would require a more aggressive treatment.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research